HOME Top Market Reports U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

By: marketsandmarkets.com
Publishing Date: July 2016
Report Code: MD 4451

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 Million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). Factors such as the growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth of the market. However, factors such as high cost of therapeutic plasma exchange procedures, lack of awareness about the TPE process, dearth of skilled professionals, and risks associated with therapeutic plasma exchange procedure are restraining the growth of the U.S. therapeutic plasma exchange market to a certain extent.

Over the past few years, the therapeutic plasma exchange market in the U.S. has witnessed stable growth. Due to the growing awareness among physicians, therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture’s syndrome, and Wegener’s Granulomatosis. This trend is expected to continue in the coming years as well.

A surge in geriatric population in the U.S. and subsequent increase in the incidence and prevalence of chronic lifestyle diseases is expected to drive the demand for therapeutic plasma exchange (TPE) for the treatment of some of the rare neurological, hematology, renal, and autoimmune disorders in the U.S. The growth of the TPE market in the U.S. can be attributed to the accessibility to technologies, superlative opportunities for TPE procedures in rare disorders, established distribution channels, and the presence of a large number of market players such as Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.) in the country.

Stakeholders of the Report:

  • Therapeutic Plasma Exchange Product Manufacturers
  • Group Purchase Organizations (GPOs)
  • OEM Manufacturers
  • Hospitals and Clinics
  • Blood Centers
  • Distributors of TPE Products
  • Healthcare Institutions
  • Research Institutes
  • Market Research and Consulting Firms
  • Venture Capitalists and Investors

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

This research report categorizes the U.S. therapeutic plasma exchange market on the basis of indication. The report also provides information on the total number of patients undergoing TPE procedures, average number of procedures per patient, and total number of TPE procedures performed in the U.S. (2015).

U.S. Therapeutic Plasma Exchange Market

This research report categorizes the U.S. therapeutic plasma exchange market into the following segments:

U.S. Therapeutic Plasma Exchange Market, by Indication

  • Neurological Disorders
  • Hematology Disorders
  • Renal Disorders
  • Autoimmune Disorders
  • Metabolic Disorders

U.S. Therapeutic Plasma Exchange Market-Patient Population & Number of Procedures Performed

Neurological Disorders

  • Guillain–Barré Syndrome (GBS)
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Myasthenia Gravis
  • Multiple Sclerosis
  • Neuromylitis Optica

Hematology Disorders

  • Thrombotic Thrombocytopenic Purpura
  • Cryoglobulinaemia
  • Multiple Myeloma
  • Waldenstrom Microglobulinaemia
  • Hemolytic Uraemic Syndrome

Renal Disorders

  • Anti-GBM Disease (Goodpasture Syndrome)
  • Wegner’s Granulomatosis (ANCA-associated Rapidly Progressive Glomerulonephritis)
  • Post Renal Transplant Rejection

Metabolic Disorders

  • Familial Hypercholesterolemia (Homozygous)

Autoimmune Disorders

  • ANCA-associated Vasculitis

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of market players such as Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Table of Contents

1 Introduction
    1.1 Objectives and Scope
    1.2 Research Methodology
    1.3 Market Estimation Methodology
    1.4 Primary Research Methodology
    1.5 Primary Respondent Profile

2 Key Insights

3 Therapeutic Plasma Exchnage Market, By Indication
    3.1 Guillain-Barré Syndrome (GBS)
    3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    3.3 Myasthenia Gravis (MG)
    3.4 Multiple Sclerosis (MS)
    3.5 Neuromyelitis Optica (NMO)
    3.6 Thrombotic Thrombocytopenic Purpura (TTP)
    3.7 Cryoglobulinemia
    3.8 Multiple Myeloma (MM)
    3.9 Waldenstrom Macroglobulinemia (WM)
    3.10 Hemolytic Uremic Syndrome (HUS)
    3.11 Anti-GBM Disease (Goodpasture’s Syndrome)
    3.12 Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
    3.13 Post-Renal Transplant Rejection
    3.14 Familial Hypercholesterolemia (Homozygous)
    3.15 Anca-Associated Vasculitis
 
4 Appendix
    4.1 Epidemiology Data
    4.2 Industry Speaks
    4.3 Details of Primary Respondents
    4.4 Available Customizations
           4.4.1 Company Profiles
                    4.4.1.1 Fresenius Se & Co. KGAA
                    4.4.1.2 B. Braun Melsungen AG
                    4.4.1.3 Baxter International Inc
                    4.4.1.4 Asahi Kasei Medical Co., Ltd.
                    4.4.1.5 Terumo BCT, Inc.
                    4.4.1.6 Haemonetics Corporation
                    4.4.1.7 Kawasumi Laboratories, Inc.
                    4.4.1.8 Hemacare Corporation
    4.5 Knowledge Store: Marketsandmarkets’ Subscription Portal


List of Tables (55 Tables)

Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014–2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market– Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Table 20 Treatment Guidelines & Protocols : Thrombotic Thrombocytopenic Purpura (TTP)
Table 21 Epidemiology : Thrombotic Thrombocytopenic Purpura (TTP)
Table 22 U.S. Disease Statistics: Cryoglobulinemia
Table 23 Treatment Guidelines & Protocols : Cryoglobulinemia
Table 24 Epidemiology : Cryoglobulinemia
Table 25 U.S. Disease Statistics: Multiple Myeloma (MM)
Table 26 Treatment Guidelines & Protocols : Multiple Myeloma (MM)
Table 27 Epidemiology : Multiple Myeloma (MM)
Table 28 U.S. Disease Statistics: Waldenstrom Macroglobulinemia (WM)
Table 29 Treatment Guidelines & Protocols : Waldenstrom Macroglobulinemia (WM)
Table 30 Epidemiology : Waldenstrom Macroglobulinemia (WM)
Table 31 U.S. Disease Statistics: Hemolytic Uremic Syndrome (HUS)
Table 32 Treatment Guidelines & Protocols : Hemolytic Uremic Syndrome (HUS)
Table 33 Epidemiology : Hemolytic Uremic Syndrome (HUS)
Table 34 U.S. Disease Statistics: Anti-GBM Disease (Goodpasture’s Syndrome)
Table 35 Treatment Guidelines & Protocols : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 36 Epidemiology : Anti-GBM Disease (Goodpasture’s Syndrome)
Table 37 U.S. Disease Statistics: Wegener’s Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis
Table 38 Treatment Guidelines & Protocols : Wegener’s Granulomatosis
Table 39 Epidemiology : Wegener’s Granulomatosis
Table 40 U.S. Disease Statistics: Post-Renal Transplant Rejection
Table 41 Treatment Guidelines & Protocols : Post-Renal Transplant Rejection
Table 42 Epidemiology : Post-Renal Transplant Rejection
Table 43 U.S. Disease Statistics: Familial Hypercholesterolemia (Homozygous)
Table 44 Treatment Guidelines & Protocols : Familial Hypercholesterolemia (Homozygous)
Table 45 Epidemiology : Familial Hypercholesterolemia (Homozygous)
Table 46 U.S. Disease Statistics: Anca-Associated Vasculitis
Table 47 Epidemiology Data
Table 48 Details of Primary Respondents (1/8)
Table 49 Details of Primary Respondents (2/8)
Table 50 Details of Primary Respondents (3/8)
Table 51 Details of Primary Respondents (4/8)
Table 52 Details of Primary Respondents (5/8)
Table 53 Details of Primary Respondents (6/8)
Table 54 Details of Primary Respondents (7/8)
Table 55 Details of Primary Respondents (8/8)


List of Figures (10 Figures)

Figure 1 Research Methodology
Figure 2 Market Estimation Methodology
Figure 3 Primary Research Methodology
Figure 4 Respondent Profile, By Organization
Figure 5 Respondent Profile, By Designation
Figure 6 Industry Speaks (1/3)
Figure 7 Industry Speaks (2/3)
Figure 8 Industry Speaks (3/3)
Figure 9 Marketsandmarkets Knowledge Store Snapshot
Figure 10 Marketsandmarkets Knowledge Store: Healthcare Industry Snapsho

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 Million by 2021, growing at a CAGR of 11% to 12% during the forecast period. The growing prevalence of neurological diseases; increasing adoption of TPE procedures in rare disorders such as Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Neuromylitis Optica, Thrombotic Thrombocytopenic Purpura (TTP), Cryoglobulinaemia; and growing awareness about increasing the clinical response rate of TPE procedures in various diseases in the U.S. are driving the growth of this market. However, factors such as high cost of therapeutic plasma exchange procedures, lack of awareness about the TPE process, lack of skilled professionals, and risks associated with therapeutic plasma exchange procedures are restraining the growth of the U.S. therapeutic plasma exchange market to a certain extent.

In this study, the U.S. therapeutic plasma exchange (TPE) market is segmented on the basis of indications. The research report discusses the total number of patients undergoing TPE procedures, average number of procedures per patient, and total number of TPE procedures performed in the U.S. (2015).

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders.

U.S. Therapeutic Plasma Exchange Market

In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. therapeutic plasma exchange market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Medical Devices Markets on KnowledgeStore
Request Demo